Drug
Ntla 2001
Ntla 2001: highest development phase Phase 3, developed by Intellia Therapeutics. 2 trial records tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- Intellia Therapeutics
Trials
| Drug | Phase | Indication |
|---|---|---|
| NTLA-2001 NCT06128629 | Phase 3 | Transthyretin Amyloidosis (ATTR) With Cardiomyopathy |
| NTLA-2001 NCT04601051 | Phase 1 | Transthyretin-Related (ATTR) Familial Amyloid Polyneuropathy |
Latest
No recent events.
Follow Ntla 2001 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.